After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO 转让管线出售股权“补血” 友芝友生物待上市自救
The cash-challenged biotech firm specializing in BsAbs and immuno-oncology therapies is turning to a Hong Kong listing to try to replenish its coffers. 这间深耕双抗靶向和肿瘤免疫疗法开发的生物科技公司财政紧绌，已向港交所申请上市筹资。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.